

Cardiovascular and Interventional Radiological Society of Europe

C **RSE** *foundation*

ET 2008 | ECIO 2008

POCKET GUIDE

**European Conference on
Embolotherapy**

**European Conference on
Interventional Oncology**

www.et2008.org | www.ecio2008.org

The Embolization Platform for Today and for the Future



Embozene™
COLOR-ADVANCED Microspheres



Distinctly Better with Polyzene®-F



CeloNova BioSciences, Inc.
49 Spring Street
Newman, GA 30263
USA

+1.888.388.3888 Toll free
celonova.com

CeloNova BioSciences
of Europe B.V.
Utrechtsestraat 38f
6811 LZ Arnhem
The Netherlands

2 General Information

- 2 Congress Registration
- 3 Important Addresses

7 Wednesday - Scientific Programme

WED

10 Thursday - Scientific Programme

THU

16 Friday - Scientific Programme

FRI

21 Saturday - Scientific Programme

SAT

24 Technical Exhibition

- 24 Technical Exhibition, Alphabetical List
- 25 Technical Exhibition, Numerical List
- 26 Technical Exhibitors Guide

General Information

Congress Registration

Online registration (secured payment) for ECIO / ET 2008 is available on **www.ecio2008.org** and **www.et2008.org**.

Onsite registration opening hours

Wednesday, April 9	07:00-18:00
Thursday, April 10	07:00-18:00
Friday, April 11	07:00-18:00
Saturday, April 12	07:00-12:00

Onsite registration fees (in Euro)

CIRSE Member	€ 550
Non Member	€ 650
Resident/Nurse/Technician	€ 160

Registration fees include access to all sessions and congress material. Reduced registration fees for ECIO / ET 2008 are only available for those CIRSE members who have been in good standing with CIRSE in 2008.

Method of Payment

Registration fees are to be paid in Euro (€) by:

- Cash
- Credit Card (or Eurocard / Mastercard)

Name changes will be handled as a cancellation and new registration.

Important Addresses

Conference Venue

Palazzo dei Congressi
Piazza Adua 1
50123 Florence, Italy

Organising Secretariat

CIRSE Central Office

Neutorgasse 9, 1010 Vienna, Austria
Tel.: +43 1 904 2003
Fax: +43 1 904 2003 30
E-mail: office@esir.org
Internet: www.ecio2008.org / www.et2008.org

Email Contacts

To obtain **general information** about the ECIO / ET 2008 meeting please e-mail us at office@esir.org
If you have any queries concerning **registration** for the ECIO / ET 2008 meeting please e-mail us at registration@esir.org
For information about the **scientific programme** of ECIO / ET 2008 please contact scientific@esir.org

CIRSE Official Travel and Housing Partner

Kuoni Incoming S.p.A.

Contact: Ms. Laura Colavalle
Via della Ferratella in Laterano, 33
00184 Rome, Italy
Tel.: +39 06 89 29 82 38
Fax: +39 06 89 29 82 36
E-mail: laura.colavalle@it.kuoni.com

Badges

Your personalised badge is your admission card to the congress. For organisational and security reasons, badges have to be worn at the congress venue at all times. A lanyard will be given to you with the congress bag. In case of loss, a replacement badge will be provided for an administrative charge of Euro 80.00. Identity checks in the congress centre may occur, which is why we kindly ask you to also carry a photographic ID with you at all times.

Certificate of Attendance

To obtain your certificate of attendance, please choose one of the following options:

Printing your certificate on site at the congress

You can print your certificate at the dedicated workstations in the registration area. All you have to do is give your last name and the login details you were given when registering for the congress.

Printing your certificate at home

After the congress you will have the possibility to print your certificate on our website (www.ecio2008.org). Again, all you will have to do is give your last name and login details in order to print out the certificate.

CME Credit Allowance

The ECIO / ET is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.be, www.uems.net.

The ECIO is designated for a maximum of 12 hours of European external CME credits. The ET is designated for a maximum of 9 hours of European external CME credits.

The ILCA session is designated for a maximum of 3 hours of European external CME credits.

Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA (www.ama-assn.org).

The Italian Health Ministry will grant credits (ECM) to ECIO 2008 and ET 2008. ECM credits will only be awarded to those who attend the entire conference. In order to obtain ECM credits, please contact the Italian Health Ministry after the number of awarded CME credits has been announced.

The ECIO is accredited by the European Society for Medical Oncology (ESMO) with 16 ESMO-MORA points Category 1.

Coffee Breaks, Snacks & Meals

The coffee break areas will be located in the Exhibition area "Passi Perduti".

Wednesday, April 9	10:00-10:30	13:15-13:30
	12:30-12:45	15:30-16:00
Thursday, April 10	12:30-13:00	16:45-17:00
	14:30-15:00	
Friday, April 11	10:45-11:15	15:30-16:00
	13:45-14:00	
Saturday, April 12	10:45-11:15	

Disclaimer

CIRSE cannot accept any liability for the acts of the suppliers to this meeting or the attendees' safety while travelling to or from the congress. All participants are strongly advised to carry adequate travel- and health insurance, as CIRSE cannot accept liability for accidents or injuries that may occur.

Mobile Phones

Please do not forget to turn off your mobile phone during all sessions.

Preview Centre

The preview centre is located on the ground floor in "Sala Onice". Please note that only digital material will be allowed for oral presentations. All material must be in English and provided on CD-ROM or USB memory stick to be placed on the central server on site. All data carriers must be delivered to the Preview Centre at least 3 hours prior to the corresponding session. Computers connected to the central server allowing access to the speakers' presentations are available in every lecture room. These computers are equipped with Microsoft Windows XP and Microsoft Office XP.

All material used in a presentation will remain the property of the speaker and will not be reused by CIRSE without his/her permission.

Speakers will not be able to use their own laptop computers for their presentations.

Preview Centre Opening Hours

Tuesday, April 8	16:00 – 19:00
Wednesday, April 9	07:30 – 19:00
Thursday, April 10	07:00 – 19:30
Friday, April 11	07:30 – 19:00
Saturday, April 12	07:30 – 13:30

Recording

Video- or audio-recording of sessions/presentations is not allowed without the speaker's/exhibitor's prior permission.

Smoking

ET/ECIO is a non-smoking congress. We therefore kindly ask all attendees to smoke outside the congress centre only.

Technical Exhibition

The ET/ECIO Technical Exhibition is located in the foyers of the Auditorium, in the "Passi Perduti".

Please find a floor plan of the exhibition on the inside of the back cover and a detailed list of all exhibitors on pages 24-25.

Technical Exhibition Opening Hours

Wednesday, April 9	09:30 - 17:30
Thursday, April 10	09:30 - 17:30
Friday, April 11	09:30 - 17:30
Saturday, April 12	09:30 - 13:45

Tourist Information and Hotel Desk

For information regarding hotels, flights, restaurants and excursions please refer to the desk of our official travel partner Kuoni in the registration area. Kuoni will be pleased to help you with all matters related to your stay in Florence.

Wednesday, April 9

08:30-10:00

Materials, tools and how to use them

Main Auditorium

Chairs: J. Lammer (Vienna/AT), G. Simonetti (Rome/IT)

How to get there: wires and catheters

M.R. Sapoval (Paris/FR)

Particles: how, when and which to choose

J.-P. Pelage (Paris/FR)

Glue and Onyx

P. Goffette (Brussels/BE)

Liquids: alcohol and sclerosing agents

P. Fourie (Johannesburg/ZA)

Coils and plugs: when, what and how to deliver

J.E. Jackson (London/UK)

Gelfoam and Ethibloc

G. Richter (Heidelberg/DE)

Embolization agent quiz

M.R. Sapoval (Paris/FR)

10:30-12:30

GI hemorrhage

Main Auditorium

Chairs: G.P. Cornalba (Milan/IT), R. Uflacker (Charleston, SC/US)

Imaging for GI hemorrhage

A.-M. Belli (London/UK)

Acute upper GI hemorrhage: when should IR get involved

A.A. Nicholson (Leeds/UK)

Acute lower GI hemorrhage: IR should always be involved

A.A. Nicholson (Leeds/UK)

Chronic GI bleeding: imaging and treatment

J.E. Jackson (London/UK)

Hemobilia and pancreatic hemorrhage

E. Brountzos (Athens/GR)

GI bleeding from HHT

R.I. White (New Haven, CT/US)

How to deal with variceal hemorrhage

S. Hirota (Hyogo/JP)

Complex cases

A.A. Nicholson (Leeds/UK)

12:45-13:15

Industry Symposium:

CeloNova Bio Science

Bland Embolization for Liver Tumors with the Novel 40 Micron Embozene™ Microsphere

Main Auditorium

F. Orsi (Milan/IT)

13:30-15:30

Trauma

Main Auditorium

Chairs: G. Feltrin (Vicenza/IT), J.A. Reekers (Amsterdam/NL)

How to set up an IR trauma service

J.C. Goslings (Amsterdam/NL)

Damage control for liver and splenic injuries

S.J.A. Sclafani (Brooklyn, NY/US)

Damage control for kidney, mesenteric and lumbar injuries

R. Uflacker (Charleston, SC/US)

When and how to embolize pelvic injuries

O.M. Van Delden (Amsterdam/NL)

Extremity injuries – embolization and stent grafts

P. Goffette (Brussels/BE)

Head and neck injuries-complex stuff

S.J.A. Sclafani (Brooklyn, NY/US)

Life threatening traumatic bleeding – case discussions

J.A. Reekers (Amsterdam/NL)

16:00-17:30

Vascular malformations 1

Main Auditorium

Chairs: L. Lupattelli (Rome/IT), R.I. White (New Haven, CT/US)

Biology and classification

P.E. Burrows (Boston, MA/US)

Running a vascular malformation policlinic

J.A. Reekers (Amsterdam/NL)

Imaging and planning

P. Rowlands (Liverpool/UK)

When to do embolization therapy and when to do surgery

H.F. Kubiena (Vienna/AT)

Embolization of high flow malformation

J.E. Jackson (London/UK)

Two complex cases

R. Gandini (Rome/IT)

17:30-19:00

Vascular malformations 2

Main Auditorium

Chairs: P. Gaines (Sheffield/UK), P. Rowlands (Liverpool/UK)

Pulmonary vascular malformation

R.I. White (New Haven, CT/US)

Sclerotherapy of low flow malformations

P.E. Burrows (Boston, MA/US)

Klippel–Trenaunay syndrome

P. Gaines (Sheffield/UK)

Congenital lymphatic malformations

P. Fourie (Johannesburg/ZA)

Head and neck vascular malformations

P. Waldenberger (Linz/AT)

Two controversial cases

J. Kettenbach (Vienna/AT)

Thursday, April 10

08:00-10:00

Embolization of the female pelvis

Sala Verde

Chairs: A.A. Nicholson (Leeds/UK), J.-P. Pelage (Paris/FR)

Uterine artery embolization: indication and imaging

T.J. Kroencke (Berlin/DE)

Uterine artery embolization: technique

R. Gandini (Rome/IT)

Uterine artery embolization: pain treatment

J.B. Spies (Washington, DC/US)

Uterine artery embolization: how to avoid complications

G. Richter (Heidelberg/DE)

Pelvic congestion syndrome

A.C. Roberts (La Jolla, CA/US)

Post-partum hemorrhage

J.-P. Pelage (Paris/FR)

Two case discussions – unexpected findings and outcome

J.B. Spies (Washington, DC/US)

10:00-12:00

CIRSE Foundation ILCA joint sessions:



Blending interventional radiology and molecular medicine Epidemiology and diagnosis of hepatocellular carcinoma

Main Auditorium

Chairs: J. Bruix (Barcelona/ES), J. Lammer (Vienna/AT)

Risk factors and cost-effective screening

M. Beaugrand (Paris/FR)

Imaging techniques for diagnosis and staging

B. Choi (Seoul/KR)

Tumour biopsy: entering molecular staging

T. Roskams (Leuven/BE)

Outcome prediction: how to refine

J. Bruix (Barcelona/ES)

**Blending interventional radiology and molecular medicine**

Main Auditorium

Chairs: J. Bruix (Barcelona/ES), B. Choi (Seoul/KR)

Assessment of gene expression by imaging

M. Kuo (SanDiego, CA/US)

Functional imaging to assess molecular therapy

V. Vilgrain (Clichy/FR)

Is RECIST still valuable in hepatocellular carcinoma

R. Lencioni (Pisa/IT)

Targeting molecular pathways in the adjuvant setting after locoregional treatment

J.M. Llovet (Barcelona/ES)

10:30-12:00

Workshops:**WS 1&2: Coils and things (Sala 101)***E. Brountzos (Athens/GR), J.A. Reekers (Amsterdam/NL)***WS 3&4: Liquid and things (Sala 104)***P.E. Burrows (Boston, MA/US), P. Fourie (Johannesburg/ZA)***WS 5&6: Glue, Onyx and things (Sala 105)***A. A. Nicholson (Leeds/UK), G.M. Richter (Heidelberg/DE),**P. Rowlands (Liverpool/UK)***WS 7&8: Particles and things (Sala 106)***J.P. Pelage (Boulogne/FR), J.B. Spies (Washington, DC/DE)*

A total of 16 Workshops will be held on Thursday. All 4 Workshop topics will be repeated 4 times to allow delegates to attend as many workshops as they are interested in. Participants will be able to follow live demonstrations about current embolotherapy materials and products.

12:00-12:30

Industry Symposium:

Bayer Healthcare

Nexavar: the new treatment paradigm in hepatocellular carcinoma

Main Auditorium

Chair: R. Lencioni (Pisa/IT)

New hope for unmet needs in advanced and recurrent hepatocellular carcinoma (HCC)

J. Bruix (Barcelona/ES)

Nexavar as the standard of care in HCC: implications for earlier stages in HCC and future directions

J.M. Llovet (Barcelona/ES)

13:00-13:45

Industry Symposium:

Terumo/Biocompatibles

Infarction end point in bland embolisation and drug-eluting beads: latest updates

Main Auditorium

Chair: A. Denys (Lausanne/CH)

UFE treatment: long term follow up of bead block registry

T.J. Kroencke (Berlin/DE)

TACE with DC bead as a pre-transplant treatment for HCC: results with anatomopathological data

P. Goffette (Brussels/BE)

International hepatic arterial embolisation registry of malignant tumours

R. Martin (Lexington, KY/US)

13:45-14:30

**Industry Symposium:
Angiodynamics**

Innovations in embolization and radiofrequency ablation

Main Auditorium

Drug-eluting bead-enhanced RF ablation of liver cancer
R. Lencioni (Pisa/IT)

Latest optimization updates of radio frequency ablation electrodes

L. Appelbaum (Jerusalem/IL)

14:30-16:00

Workshops:

WS 1&2: Coils and things (Sala 101)

E. Brountzos (Athens/GR), J.A. Reekers (Amsterdam/NL)

WS 3&4: Liquid and things (Sala 104)

P.E. Burrows (Boston, MA/US), P. Fourie (Johannesburg/ZA)

WS 5&6: Glue, Onyx and things (Sala 105)

A. A. Nicholson (Leeds/UK), G.M. Richter (Heidelberg/DE),

P. Rowlands (Liverpool/UK)

WS 7&8: Particles and things (Sala 106)

J.P. Pelage (Boulogne/FR), J.B. Spies (Washington, DC/DE)

A total of 16 Workshops will be held on Thursday. All 4 Workshop topics will be repeated 4 times to allow delegates to attend as many workshops as they are interested in. Participants will be able to follow live demonstrations about current embolotherapy materials and products.

15:00-16:45

Clinical Focus Session:

Early-stage hepatocellular carcinoma

Main Auditorium

Chairs: M. Colombo (Milan/IT), J.-F. Geschwind (Baltimore, MD/US)

Clinical overview and BCLC staging

L. Bolondi (Bologna/IT)

Current approaches in surgical resection

G. Torzilli (Milan/IT)

Transplantation versus resection

V. Mazzaferro (Milan/IT)

Interventional treatment of patients awaiting transplantation

L. Crocetti (Pisa/IT)

Transplantation after interventional down staging

F. Filippini (Pisa/IT)

Percutaneous ablation: chemical vs thermal

P.R. Mueller (Boston, MA/US)

Prevention of recurrence after curative treatments

M. Colombo (Milan/IT)

15:00-15:45

Workshop:

Radioembolization of liver malignancies: techniques

Sala Verde

Chair: C. Ferro (Genoa/IT)

T. Helmberger (Munich/DE), J.I. Bilbao (Pamplona/ES)

16:00-16:45

Workshop:

Intra-arterial liver treatments: technical tips

Sala Verde

Chair: A. Siani (Naples/IT)

C. Vignali (Pisa/IT), F. Orsi (Milan/IT)

17:00-18:45

Clinical Focus Session:

Intermediate-advanced hepatocellular carcinoma

Main Auditorium

Chairs: J. Bruix (Barcelona/ES), G. Simonetti (Rome/IT)

Chemoembolization: protocols and outcomes

G.P. Cornalba (Milan/IT)

Bland embolization vs chemoembolization

G. Getrajdman (New York, NY/US)

Chemoembolization with drug-eluting beads:
experimental studies

J.-F. Geschwind (Baltimore, MD/US)

Chemoembolization with drug-eluting beads:
clinical trials

J. Lammer (Vienna/AT)

Combined chemoembolization and ablation

R. Lencioni (Pisa/IT)

Radioembolization

R. Salem (Chicago, IL/US)

Targeted systemic therapy

J.M. Llovet (Barcelona/ES)

Recommendations for future research

J. Bruix (Barcelona/ES)

18:45-19:30

Welcome-Honorary Lecture

Main Auditorium

Chairs: A. Adam (London/UK), G.P. Cornalba (Milan/IT),

R. Lencioni (Pisa/IT)

Welcome by the President of the CIRSE Foundation

J. Lammer (Vienna/AT)

Welcome by the President of the Italian Society of Radiology

R. Lagalla (Palermo/IT)

Welcome by the President of the Italian Interventional
Radiology Section

G. Gandini (Turin/IT)

Honorary Lecture:

The future of cancer imaging and intervention

H. Hricak (New York, NY/US)

WELCOME RECEPTION

Congress Centre/Limonaia

Please join us for the ET/ECIO Welcome Reception!

Friday, April 11

08:30-10:15

Clinical Focus Session:

Colorectal hepatic metastases

Main Auditorium

Chairs: P.F. Conte (Modena/IT), M. Montorsi (Milan/IT)

Clinical overview and systemic chemotherapy

A. Falcone (Pisa/IT)

Outcomes of surgical resection

M. Montorsi (Milan/IT)

Outcomes of percutaneous ablation

L. Solbiati (Busto Arsizio/IT)

Chemoembolization

M. Soulen (Philadelphia, PA/US)

Radioembolization

J.I. Bilbao (Pamplona/ES)

Percutaneously implanted ports for intra-arterial chemotherapy

Y. Arai (Tokyo/JP)

Intra-arterial treatment with drug-eluting beads

C. Aliberti (Portomaggiore/IT)

Special topic: interventional treatment of

endocrine metastases

T. de Baère (Villejuif/FR)

08:30-9:15

Workshop:

Extra hepatic ablation: technical tips

Sala Verde

Chair: B. Lees (London/UK)

A. Veltri (Turin/IT), J. Palussière (Bordeaux/FR)

09:30-10:15

Workshop:

How I do it: chemoembolization with drug eluting beads

Sala Verde

Chair: M. Grosso (Cuneo/IT)

R. Golfieri (Bologna/IT), K. Malagari (Athens/GR)

10:45-11:45

Clinical Focus Session:

Kidney tumours

Main Auditorium

Chairs: P.R. Mueller (Boston, MA/US), R. Pozzi Mucelli (Verona/IT)

Clinical overview and surgical management

C. Bremer (Münster/DE)

Patient selection and indications for percutaneous ablation

T. Helmberger (Munich/DE)

Outcomes of RF ablation

D. Breen (Southampton/UK)

Cryoablation vs RF ablation

D. Gervais (Boston, MA/US)

Current role of embolization in kidney tumours

M.J. Lee (Dublin/IE)

10:45-11:45

Workshop:

Liver ablation: technical tips

Sala Verde

Chair: L. Crocetti (Pisa/IT)

C.T. Sofocleous (NewYork, NY/US), R.-T. Hoffman (Munich/DE)

12:15-13:00

Industry Symposium:

Bracco

Contrast enhanced ultrasound in diagnosis and percutaneous treatment procedure - the winning situation

Main Auditorium

Chairs: G.P. Cornalba (Milan/IT), R. Lencioni (Pisa/IT)

The role of contrast enhanced ultrasound in HCC patient for diagnosis and during percutaneous treatment

C. Nicolau (Barcelona/ES)

Contrast enhanced ultrasound and fusion imaging:

the optimal combination to guide and monitor percutaneous treatment

L. Solbiati (Busto Arsizio/IT)

Diagnostic performance of CEU's in the follow-up of cancer patient

S. Yarmenitis (Heraklion/GR)

13:00-13:45

Industry Symposium:

Boston Scientific

Combined treatment in hepatocellular carcinoma: radiofrequency ablation prior or after TACE?

Main Auditorium

RFA prior TACE

P. Chevallier (Nice/FR)

RFA after TACE

A. Denys (Lausanne/CH)

Discussion

14:00-15:30

Clinical Focus Session:

Lung tumours

Main Auditorium

Chairs: L. Bonomo (Rome/IT), D.E. Dupuy (Providence, RI/US)

Clinical overview and surgical management

C. Fernando (Boston, MA/US)

Ablation outcomes: primary lung cancer

R. Lencioni (Pisa/IT)

Ablation outcomes: metastases

T. de Baère (Villejuif/FR)

Complications of lung ablation

L. Crocetti (Pisa/IT)

Combined ablation and radiation therapy

D.E. Dupuy (Providence, RI/US)

Intra-arterial chemoembolization

T. Vogl (Frankfurt/DE)

Special topic: bronchial artery embolization

M.J. Lee (Dublin/IE)

16:00-18:00

Technical Focus Session:

What's new in ablation devices and transarterial agents

Main Auditorium

Chairs: J.-F. Geschwind (Baltimore, MD/US), R. Lencioni (Pisa/IT)

Ethanol ablation

M.-D. Lu (Guangzhou/CN)

Chemical ablation and electrolysis

M. Soulen (Philadelphia, PA/US)

Radiofrequency ablation

R. Lencioni (Pisa/IT)

Microwave ablation

F. Lee (Madison, WI/US)

Cryoablation

M. Callstrom (Jacksonville, FL/US)

Focused ultrasound

S. Solomon (New York, NY/US)

Electroporation

G. Onik (Celebration, FL/US)

Intra-arterial therapies using tumour metabolism inhibitors

J.-F. Geschwind (Baltimore, MD/US)

18:15-19:00

Industry Symposium:

Covidien

MWA, a new milestone within ablative therapies

Main Auditorium

Chair: L. Solbiati (Busto Arsizio/IT)

Basic physics and biophysics of microwave ablation

J. Case (Boulder, CO/US)

Microwave vs. radiofrequency: lessons learned from experimental animal studies

L. Crocetti (Pisa/IT), R. Lencioni (Pisa/IT)

MWA: overview of current and future clinical applications in patients

D.E. Dupuy (Providence, RI/US)

Saturday, April 12

08:30-10:00

Technical Focus Session:

Imaging guidance, monitoring and follow-up

Main Auditorium

Chairs: C. Bartolozzi (Pisa/IT), R. Passariello (Rome/IT)

Contrast ultrasound and real-time fusion imaging

L. Solbiati (Busto Arsizio/IT)

Angio-CT

Y. Arai (Tokyo/JP)

MR imaging

P. Pereira (Tübingen/DE)

Robotics

S. Solomon (New York, NY/US)

Imaging assessment of tumour viability

C. Bartolozzi (Pisa/IT)

Tumour response criteria in interventional oncology

D. Cioni (Pisa/IT)

10:00-10:45

Industry Symposium:

GE Healthcare

Innovation and practical applications in breast and liver cancer.

New interventional solutions and applied imaging technologies

Main Auditorium

Chair: D. Gianfelice (Laval/CA)

Changing demographics of cancer in Europe

D. Gianfelice (Laval/CA)

Innovative approaches improve breast cancer outcomes

D. Gianfelice (Laval/CA)

Abdominal cancer. New interventional solutions and applied imaging technologies.

T. de Baère (Villejuif/FR)

11:15-11:45

Industry Symposium:

Philips

Contrast-enhanced ultrasound for interventional oncology

Main Auditorium

The role of 3D CEUS in assessing the efficacy of radiofrequency ablation of HCC and the role of quantitative techniques for the evaluation of the efficacy of antitumoral treatments

C. Serra (Bologna/IT)

11:45-12:45

Clinical Focus Session:

Bone tumours

Main Auditorium

Chairs: B. Charboneau (Jacksonville, FL/US),

M. Hicks (Houston, TX/US)

Cryoablation

S. Masala (Rome/IT)

Ablation: indications and patient selection

A. Kelekis (Athens/GR)

Treatment of osteoid osteoma

A. Gangi (Strasbourg/FR)

Ablation of bone metastases

B. Charboneau (Jacksonville, FL/US)

Intra-arterial therapy of bone metastases

J. Chiras (Paris/FR)

Combined RF ablation and cementoplasty

G. Anselmetti (Turin/IT)

11:45-12:45

Workshop:

Complications of percutaneous ablation

Sala Verde

Chair: O. Akhan (Ankara/TR)

M. Bezzi (Rome/IT), T. Jakobs (Munich/DE)

12:45-13:45

Clinical Focus Session:

New applications

Main Auditorium

Chairs: M. Brunner (Chicago, IL/US),

G. Dorfman (Worcester, MA/US)

Head and neck

M. Mack (Frankfurt/DE)

Breast

S. Klimberg (LittleRock, AR/US), G. Manenti (Little Rock, AR/US)

Prostate

G. Onik (Celebration, FL/US)

Pelvis and retro peritoneum

A. Gillams (London/UK)

Focused ultrasound ablation of thyroid nodules

L. Leenhardt (Paris/FR), O. Esnault (Boulogne-Billancourt/FR)

Special topic: future research in interventional oncology

G. Dorfman (Worcester, MA/US)

Technical Exhibition (Alphabetical List)

Official Name	Booth
AB MEDICA	10
AGA MEDICAL	21
ANGIODYNAMICS	2
ARTHROCARE SPINE	7
BIOSPHERE MEDICAL	4
BOSTON SCIENTIFIC	6
BRACCO IMAGING	19
CELON MEDICAL INSTRUMENTS	12
CELONOVA BIOSCIENCES	8
COOK MEDICAL	15
COVIDIEN	13
ESAOTE	11
EV3	17
GALIL MEDICAL	22
GE HEALTHCARE	3
HS HOSPITAL SERVICE	20
MDS NORDION	9
PHILIPS HEALTHCARE	14
SIEMENS HEALTHCARE	5
SIRTEX MEDICAL EUROPE	16
TERUMO	18
WISEPRESS ONLINE BOOKSHOP	1

Technical Exhibition (Numerical List)

Booth	Official Name
1	WISEPRESS ONLINE BOOKSHOP
2	ANGIODYNAMICS
3	GE HEALTHCARE
4	BIOSPHERE MEDICAL
5	SIEMENS HEALTHCARE
6	BOSTON SCIENTIFIC
7	ARTHROCARE SPINE
8	CELONOVA BIOSCIENCES
9	MDS NORDION
10	AB MEDICA
11	ESAOTE
12	CELON MEDICAL INSTRUMENTS
13	COVIDIEN
14	PHILIPS HEALTHCARE
15	COOK MEDICAL
16	SIRTEX MEDICAL EUROPE
17	EV3
18	TERUMO
19	BRACCO IMAGING
20	HS HOSPITAL SERVICE
21	AGA MEDICAL
22	GALIL MEDICAL

Technical Exhibitors Guide

ab medica spa

Booth 10

Tel.: +39 02933051

Fax: +39 0293305400

web: www.abmedica.it

email: abmedica@abmedica.it

AB Medica spa, funded in 1984, is the proud partner to a growing number of medical device companies worldwide. We have completed more than 20 years of dramatic growth and distribute over €60 Millions of doctor preference products every year to over 600 Italian hospitals. We specialize in Cardiology, Surgery, Radiology and Medical Robotics (www.abmedica.it)

AGA Medical Corporation

Booth 21

Toll Free: 1-888-546-4407

Phone: 1-763-513-9227

Fax: 1-763-513-9226

web: www.amplatzer.com

AGA Medical Corporation, based in Minneapolis, Minnesota, is the world's leading manufacturer of implantable occlusion devices that enable minimally invasive treatment for a range of congenital heart defects and peripheral vascular disorders. As a result of the many contributions and creative genius of Dr. Kurt Amplatz, the Company has developed and commercializes a series of devices that have revolutionized the treatment of the most common congenital "holes in the heart" such as atrial septal and patent foramen ovale defects. The AMPLATZER Vascular Plug is the first of the company's devices intended for use by interventional radiologists and is indicated for arterial and venous embolizations in the peripheral vasculature.

AngioDynamics, Inc.

Booth 2

Tel.: 001 518 798 1215

Cell: 001 518 796 2137

web: www.angiodynamics.comemail: kostrander@angiodynamics.com

AngioDynamics (www.angiodynamics.com) is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. AngioDynamics' diverse product line includes radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products.

ArthroCare Spine

Booth 7

Tel.: +46 8 546 172 00

Fax: +46 8 546 172 39

web: www.arthrocare.comemail: spine@arthrocare.se

ArthroCare Spine is a highly innovative, multi-business medical device company that develops, manufactures and markets products based on its internationally patented Coblation® technology. This platform technology has led to the improvement of existing procedures and the development of new minimally invasive procedures. Our devices have been used in millions of cases worldwide across several medical specialties.

Procedures such as Nucleoplasty® and Percutaneous Vertebroplasty have helped thousands of patients return to active and productive lives. The addition of the Cavity™ SpineWand™, designed for the removal of spinal tumours, further expands the exciting Spine product range.

Please visit the ArthroCare booth to learn more about our exciting technology and applications.

BioSphere Medical

Booth 4

Tel.: +33 1 48 17 25 25

Fax: +33 1 49 38 02 68

web: www.biospheremed.comemail: info@biospheremed.fr

BioSphere Medical has established its reputation as the market leader in the spherical particulate embolization field with its proprietary core technology, Trisacryl microspheres: EmboSphere® and EmboGold® microspheres. The superiority and clinical efficacy of EmboSphere® and EmboGold® has been proven and reported in more than 80 internationally recognized publications and peer reviewed journals.

BioSphere Medical offers a complete hydrophilic embolization platform with its infusion catheter, EmboCath® Plus and its steerable guidewire, Sequitor™.

With the new addition of HepaSphere™ microspheres, BioSphere Medical has developed the next generation of spherical embolic material that enables the clinician to perform Targeted liver embolization utilizing the unique Absorbing, Conforming and Expanding features inherent to Hepasphere. HepaSphere™ microspheres have been made available in Europe for the embolization and treatment of hepatocellular carcinoma and hypervascular liver tumors. Additionally, HepaSphere™ microspheres can be loaded with Doxorubicine for use in chemoembolization.

QuadraSphere™ is another new generation of embolic based on the same technology as HepaSphere™.

Boston Scientific International S.A.

Booth 6

Tel : +33 1 57 66 80 00

Fax : + 33 1 57 66 84 99

web: www.bostonscientific.comweb: www.bostonscientific-international.com

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.

For more than 25 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties.

The company's products help physicians and other medical professionals save lives and improve the quality of life for patients by providing alternatives to major surgery and other medical procedures that are typically traumatic to the body. In less-invasive procedures, devices are usually inserted into the body through natural openings or small incisions and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems.

Bracco Imaging SpA

Booth 19

www: www.braccoimaging.com.

Bracco Imaging SpA, part of Bracco Group, is one of the world leading companies in the imaging agent business.

One of the independent players in its sector, it is headquartered in Milan (Italy) and operates in over 80 markets worldwide, either directly or indirectly through subsidiaries, joint ventures, license and distribution partnership agreements.

Bracco Imaging provides a large portfolio of imaging agents, products used during diagnostic imaging procedures to enhance anatomic and functional visualization of internal body organs and areas. Its products are available for all the main key modalities, including: X-Ray Imaging (conventional X-Ray and Computed Tomography-CT), Magnetic Resonance Imaging (MRI), Ultrasound Imaging, and Nuclear Medicine Imaging through radioactive tracers.

Bracco Imaging's products include:

SonoVue, intravenous Ultrasound contrast agent for cardiac, neurological and radiological applications, available in Europe and China.

Iopamidol and Iomeprol: non ionic iodinated contrast agents for X-Ray.

ProHance and MultiHance, contrast agents for MRI.

Investments in operations have been made by Bracco Imaging in order to achieve top quality and compliances with sustainable ecology friendly production. Manufacturing activities are located in Italy, Switzerland, Japan and China.

For more information about Bracco Imaging, please visit our website: www.braccoimaging.com.

Celon AG medical instruments

Booth 12

Tel.: +49 3328 35 19 0

Fax: +49 3328 35 19 23

web: www.celon.comemail: info@celon.com

Celon AG medical instruments (www.celon.com), a wholly owned subsidiary of Olympus, develops innovative medical products in the field of minimally invasive medicine. At the core of its research, development and production activities is the company's proprietary technology called "Bipolar Radiofrequency Induced Thermotherapy" (RFITT®). Based on this technology, which is protected through numerous international patents, Celon provides a platform of products in ENT, surgery, gastroenterology and phlebology. Founded in 1999 and based in Teltow near Berlin, Celon employs today 50 people.

CeloNova BioSciences Inc

Booth 8

Tel: +1 770 502 03 04

Fax: +1 770 502 07 73

Headquartered in Newnan, near Atlanta, Georgia, CeloNova BioSciences, Inc., is a developer of novel medical devices based on the company's patented Polyzene®-F surface coating technology. Polyzene®-F is highly lubricious, and possesses both bacterial resistant and anti-inflammatory properties that make it an ideal surface treatment for implanted medical devices. The company's current product portfolio includes Embozene™ Color-Advanced Microspheres and the CATANIA™ Coronary Stent System with NanoThin Polyzene®-F. Embozene™ Microspheres are the only embolization microsphere that is color-coded by size, allowing instant visual confirmation of size, location, and suspension. The nanothin surface of the CATANIA™ Coronary Stent is proven to prevent thrombosis, prevent restenosis, and resist bacterial infection. It also promotes rapid endothelial cell growth which is verifiable by optical coherence tomography. Because there are no drugs on it, patients who receive the CATANIA™ Stent do not have to take long-term dual anti-platelet therapy.

Cook Medical**Booth 15**

Tel.: +45 56 86 86 86

Fax: +45 56 86 86 96

web: www.cookmedical.comemail: Andrew.Conder@cookmedical.com

Cook Medical was the first company to introduce interventional devices in the United States. Today, the company participates in all global markets, integrating device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology and assisted reproductive technology; gynecology and high risk obstetrics. For more information, visit www.cookmedical.com

Covidien AG**Booth 13**web: www.covidien.comemail: elise.boudghene@covidien.com

Covidien manufactures, distributes and services an extensive product line. With industry-leading brand names, like the well-established Imaging products, Covidien is present in virtually every healthcare setting.

Covidien is a major supplier in the field of X-Ray imaging, nuclear medicine and interventional radiology, providing diagnostic and therapeutical products, such as contrast agents, power injectors, radioisotopes and ablative therapy solutions. These products are used by specialists with equipment like CT, MRI, Gamma cameras and Ultrasound. They give important information about diseases and show effectiveness in therapeutical measures. With the interventional oncology product portfolio Covidien offers the most up to date treatment options for the Interventional Radiologist.

All Covidien divisions are committed to training and education programmes that support all aspects of healthcare practices, particularly in the hospital environment and beyond, which improves outcomes for patients across the world.

At ET / ECIO Covidien mainly exhibits the Cool-tip™ Radiofrequency Ablation System and Microwave Ablation with VivaWave™.

Please visit Covidien in congress exhibition hall.

Esaote S.p.A.

Booth 11

Tel.: +39 055 4229 1

Fax: +39 055 4229 208

web: www.esaote.com

email: international.sales@esaote.com

The Esaote Group is a global leader in research, production and marketing of medical diagnostic equipment focused on solving the medical needs of radiologists worldwide. With over 16% of its employees engaged in R&D, Esaote is pursuing new diagnostic targets such as Interventional Radiology to be enhanced on the Healthcare Markets for Customer's satisfaction and support.

At ET/ECIO 2008 Esaote is proud to show the MyLab Ultrasound Product Line. Particular emphasis will be focused on the MyLab70XVG able to run integrated Virtual Navigator technology. Virtual Navigator technology is a revolutionary modality introduced for the first time by Esaote, which provides real-time fusion of ultrasound and CT/MR imaging.

Furthermore all MyLab product line systems are brilliant with their performances, new design and keyboard ergonomics as well. Moreover, the latest SW release of all the products on show will be presented with real-time-scanning. The wide product range and the unique modularity and scalability are able to satisfy any clinical needs, providing reliable solutions, from the entry level up to the most demanding one. Connectivity and data sharing capability of the MyLab Product Line are simply the most updated ones, since ergonomics, users' comfort and productivity are well known characteristics of Esaote products.

ev3

Booth 17

Tel.: +33.156.88.59.10

Fax.: +33.156.88.59.11

web: www.ev3.net

ev3 is a global leader and single, best-in-class technology provider for specialists treating a wide range of vascular diseases and disorders. ev3 is committed to the peripheral vascular and neurovascular markets offering the most comprehensive portfolio of treatment options available, including the primary interventional technologies used today - plaque excision systems, PTA balloons, stents, embolic protection, thrombectomy, neuro coils, liquid embolics, occlusion balloons and procedural support.

With a legacy in technology development and innovation, ev3 is helping endovascular specialists around the world perform more efficiently, effectively and predictably.

ev3's singular mission is to help our customers improve the quality of their patients' lives through the development of innovative endovascular technologies and emerging therapies.

ev3. Giving life to endovascular excellence.

Galil Medical UK Limited

Booth 22

Tel.: +44 1293 459848

Fax: +44 1293 459840

web: www.galil-medical.comemail: info@galilmedical.com

Galil Medical is leading a new era of minimally invasive cryotherapy solutions that enhance patient quality of life. Since its foundation, Galil Medical has dedicated extensive research toward increasing the ease of use and precision of cryotherapy and minimally invasive procedures in order for physicians to provide patients with rapid recovery times and a high quality of life.

Cryotherapy ablation has been widely used for the treatment of prostate and kidney cancer. New ablation treatments for various other tumors are being developed in the Women's Health and Interventional Radiology markets.

MRI SEEDNET™ combines powerful freezing technology with advanced 17-gauge (1.47mm) needle technology to offer an easy-to-use system which offers improved ablation through visualization and protection of adjacent structures. The wide range of needles makes MRI SEEDNET suitable for a variety of applications and offers operator choice of iceball size.

GE Healthcare

Booth 3

Tel.: +33 (0)1 30 70 94 18

Fax: +33 (0)1 30 70 94 35

web: www.gehealthcare.com

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enables healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a \$17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

HS Hospital Service SpA

Booth 20

Tel: + 39 06 9201961

Fax: + 39 06 9275519

web: <http://www.hshospitalservice.com>email: hs@hshospitalservice.com

H.S. Hospital Service SpA. is a medical device company which has been acting in the medical market for over 25 years, keeping up with the various market developments. Starting from 1996, the Company geared up with equipment for manufacturing and marketing its own brand and its own CE mark not only in Italy, but all over the world. H.S. Hospital Service S.p.A. incorporated a US subsidiary in Boca Raton - Florida which distributes H.S. products (FDA approved) in the US and in Latin America. H.S. latest investments have been focused on R&D, in line with its view towards a better and improved clinical technique.

In this respect H.S. Hospital Service S.p.A. developed over the years products with the specific aim of improving the patient's quality of life during medical treatment administration. Critical care disposable devices constitute a significant part of H.S. production. H.S. focuses on hitting the market with products whose use could help relieve those patients who are treated with a long term therapy, such as cancer patients and IC patients. Eliminating pain and discomfort is H.S.'s main goal.

In particular 3 years ago H.S. R&D department has begun a project in the field of infusion device and has realized a disposable preset electronic infusion pump for each continuous and not infusion schedule.

MDS Nordion

Booth 9

Tel.: 001 (866) 363-3330

Fax: 001 (613) 592-6815

web: www.therasphere.comemail: therasphere@mdsinc.com

TheraSphere: an innovative treatment for liver cancer. TheraSphere is a powerful yttrium-90 therapy delivering uniform, targeted internal radiation and is a safe treatment option for liver cancer. TheraSphere is available in patient

specific dosing and is the only treatment option for HCC patients with PVT. It offers downstaging to resection ability and shows minimal side effects when compared with systemic treatments.

Philips Healthcare

Booth 14

Tel.: +49 7031 463 2254

web: www.medical.philips.comemail: derek.delahunt@philips.com

Philips Healthcare provides imaging systems to support the planning, guidance and follow up of interventional procedures. Philips iU22 provides the most advanced and comprehensive contrast-enhanced ultrasound (CEUS) solutions for the detection, characterization, treatment and monitoring of focal hepatic lesions and other solid tumors throughout the body. With advanced pulsing technologies such as power modulation/pulse inversion and coded contrast harmonics, the new C5-1 PureWave transducer provides unmatched penetration and resolution of contrast microbubbles across vascular and parenchymal phases. In addition, the transducer's narrow footprint provides easier intercostal access to challenging anatomy such as obstructed cirrhotic livers.

Siemens AG Healthcare

Booth 5

Tel.: +49 (0) 9131 / 84-0

Fax: +49 (0)9131 / 84-2924

web: www.siemens.com/healthcareemail: med.kbc.gms@siemens.com

Siemens Healthcare is one of the world's largest suppliers to the healthcare industry. The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration. With its laboratory diagnostics acquisitions, Siemens Healthcare will be the first fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technol-

ogy solutions, supplemented by consulting and support services. Siemens Healthcare delivers solutions across the entire continuum of care - from prevention and early detection, to diagnosis, therapy and care. The company employs more than 49,000 people worldwide and operates in 130 countries. Further information can be found by visiting <http://www.siemens.com/healthcare>

Sirtex Medical Europe GmbH**Booth 16**

Tel.: + 49 (228) 18407 30

Fax: + 49 (228) 18407 35

web: www.sirtex.comemail: info@sirtex-europe.com

Sirtex Medical Europe GmbH is a wholly owned subsidiary of Sirtex Medical Pty Ltd, a publicly listed company on the Australian Exchange engaged in the field of oncology and interventional oncology. Our innovative technology, SIR-Spheres® microspheres, was approved for use in the treatment of unresectable liver cancer within the European Union under a CE Mark in October 2002. FDA approval in the United States was granted in March 2002. SIR-Spheres microspheres is presently employed in the treatment of a variety of unresectable metastatic liver tumours as well as in hepatocellular carcinoma at 27 institutions within the European Union including Austria, Belgium, Germany, Italy, Spain, Sweden and United Kingdom.

Terumo Europe**Booth 18**

Tel.: +33 (0)1 39 30 95 75

Fax: +33 (0)1 39 30 95 70

web: www.terumo-europe.comemail: info@terumo-europe.com

Pioneering the development of high performance medical devices for minimally invasive therapies, Terumo & Biocompatibles are offering you the best solution with their innovative Embolotherapy systems. By matching the Bead Block™ embolization microspheres from Biocompatibles with

the leading edge access and delivery systems from Terumo (GT Microguidewires, Progreat™ microcatheters), you can perform embolization procedures in a safer, faster and more comfortable way than ever.

Innovating in the field of Interventional Oncology, Biocompatibles has developed the unique concept of Drug Chargeable Beads (DC Bead™), the only drug delivery embolization system designed, clinically validated and CE approved for Trans Arterial Chemo-Embolization (TACE) of hypervascularized tumors presently proposed on the market. DC Bead™ is exclusively distributed in Europe by Terumo. For more information, come and visit us on Terumo booth.

Wisepress Online Bookshop Ltd

Booth 1


Tel.: +44 20 8715 1812

Fax: +44 20 8715 1722


web: www.wisepress.com

email: bookshop@wisepress.com


Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you - Wisepress will deliver worldwide. In addition to attending 250 conferences per year, Wisepress has a comprehensive medical and scientific bookshop online with great offers, some up to 40% off the publisher list prices.




Entrance Level




Ground Floor



First Floor



Second Floor



DC Bead™ Drug Delivery Embolisation System for PRECISION TACE



PRECISION TACE with DC Bead™

Addressing the challenge of improved survival
in hepatocellular carcinoma

% Probability of Survival		Publication
12 Months	24 Months	PRECISION TACE with DC Bead™
98	91	Malagari et al, 2007 ¹
93	89	Valela et al, 2007 ²
12 Months	24 Months	Conventional TACE
82	63	Llovet et al, 2002 ³
24	15	Groupe CHC, 1998 ⁴
57	31	Lo et al, 2002 ⁵

“ Chemoembolisation improves survival of stringently selected patients with unresectable hepatocellular carcinoma ” *Llovet et al, 2002³*

“ The 1 and 2 year survival [with DC Bead] is 92.5% and 88.9% respectively. With a median follow up of 27.6 months ” *Valela et al, 2007²*

“ Survival at 12 months follow up [with DC Bead] was 97.1%. 18 months 94.1% 24 months 91.1% 30 months was 88.2% ” *Malagari et al, 2007¹*

TERUMO EUROPE NV
Researchpark Zone 2,
Hasseltsesteenweg 40,
B-3001 Lommel, Belgium
Tel: +32 (0) 16 38 12 11
Fax: +32 (0) 16 40 00 49
Email: info@terumo-europe.com
www.terumo-europe.com

References:
1. Malagari, K., Avezopoulos, E., Chalonachal, K., et al. Abdominal imaging. November 2006
2. Valela, M., Peck, M., Burrell, M., et al. Journal of Hepatology 46 (2007) 474-481
3. Llovet, J.M., Real, M.I., Montana, X., et al. Lancet 2002; 359: 1734-1739
4. Pelleker et al and CHC. Journal of Hepatology 1998; 29:129-134
5. Lo, G.M., Ngai, H., Tai, P.W. et al. Hepatology 2002;35: 1164-1171.

DC Bead™ is a trademark of
Biocompatibles UK Ltd.

DC Bead™ is not currently available for sale
or distribution in the USA.

© 2007 Biocompatibles UK Ltd.
11/0812 Rev 2

Manufactured by
TERUMO
We keep life moving

Biocompatibles

